SHANGHAI, Jan. 5, 2015 /PRNewswire/ — WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States, announced the launch of WuXi V-Lab, the first mobile app available to the global research community in need of small-molecule compound synthesis. WuXi V-Lab allows customers to request organic compound synthesis through a mobile device with ease, speed, and flexibility. The application provides online functions for inquiry, quotation, order confirmation, project tracking, delivery confirmation, and payment. WuXi V-Lab can be downloaded to an Apple or Android mobile device at: http://www.wuxiapptec.com/WXVLab

“WuXi is one of the world’s largest employers of chemists and a recognized leader in premier chemistry services,” said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. “We are committed to integrating best-in-class R&D capabilities with cutting-edge mobile technologies to enable innovation-on-the-go by anyone, at any time, anywhere.”

About WuXi PharmaTech

WuXi PharmaTech (NYSE: WX) is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech’s services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

For more information, please contact:

Ronald Aldridge

Director of Investor Relations

+1 (201) 585-2048

[email protected]